Abstract

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2019-01-25T17:30:27Z No. of bitstreams: 1 LAROCCA,T.F. Assessment of syndecan-4...2018.pdf: 10166331 bytes, checksum: 0c3c0d4a7677f38a2fd443a1fc5f6d95 (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2019-01-25T17:58:58Z (GMT) No. of bitstreams: 1 LAROCCA,T.F. Assessment of syndecan-4...2018.pdf: 10166331 bytes, checksum: 0c3c0d4a7677f38a2fd443a1fc5f6d95 (MD5)Made available in DSpace on 2019-01-25T17:58:58Z (GMT). No. of bitstreams: 1 LAROCCA,T.F. Assessment of syndecan-4...2018.pdf: 10166331 bytes, checksum: 0c3c0d4a7677f38a2fd443a1fc5f6d95 (MD5) Previous issue date: 2018National Council for Research (CNPq), Research Foundation of Bahia State (FAPESB), and Funding Authority for Studies and Projects (FINEP).Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade federal da Bahia. Salvador, BA, Brasil.Messejana Hospital. Fortaleza, CE, Brasil.Messejana Hospital. Fortaleza, CE, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Chronic Chagas cardiomyopathy (CCC) is characterized by the presence of a multifocal inflammatory response and myocardial damage, leading to fibrosis, arrhythmias and ventricular dysfunction. The expression of syndecan-4, a transmembrane proteoglycan, was previously found to be increased in the hearts of mice chronically infected with Trypanosoma cruzi. The possible involvement of syndecan-4 in the disease pathogenesis, however, remains unknown. Here we evaluated the pattern of expression of syndecan-4 in the heart tissue of T. cruzi infected mice and subjects with Chagas cardiomyopathy, correlating with the degree of inflammation and fibrosis

    Similar works